Oncotelic Launches Therapeutics AI-Powered PDAOAI For Advanced Document Search

Oncotelic Therapeutics, Inc. has introduced its new generation A.I. system called PDAOAI for efficiently searching and analysing documents in knowledge-based fields, including pharmaceuticals and biotechnology. Over the past year, the newly developed PDAOAI has more accurately targeted large datasets and is a definitive improvement over traditional AI systems.

Scott Myers, Product Manager, Oncotelic, said in a statement, "This is just one of many solutions we have planned for PDAOAI. We are excited to see the successful implementation of PDAOAI at SAPU's GMP facility. This rapid onboarding into GMP is just the beginning."

PDAOAI is different from other AI chatbots, whereby after launching a general search. PDAOAI uses a semantic filter and LLM contextual responding. This way, the platform provides not only specific and very detailed analysis of large datasets that the organisation may be managing as the library of research articles, scientific publications, or enterprise knowledge bases but also does it quickly and efficiently. It’s based on the proprietary patented solution and provides nearly perfect accuracy even as it is virtually infinitely extendable.

"This combination of semantic filtering and contextual question-answering, applied at the document level, has proved to be a game-changer in our approach to document searching, analysis and summarisation, " commented Mike Potts, VP of Data Science, Oncotelic.

Targeted at enterprise users and scientists, the platform currently focuses on the biotechnology sector. One notable application has been by Sapu Bioscience, LLC, a subsidiary of GMP Biotechnology (45% owned by Oncotelic). The platform was instrumental in training employees and establishing standard operating procedures (SOPs), enabling the facility to achieve GMP compliance within a year. This accelerated employee development, transforming staff from entry-level proficiency to expert levels in record time.

Saran Saund, Chief Business Officer, Oncotelic, said, "PDAOAI is already driving value for Sapu Biosciences, enabling advancements beyond GMP compliance and accelerating drug development. We look forward to introducing new capabilities as they become available. Looking ahead, we plan to expand the platform's applications beyond life sciences, focusing on semiconductors, where it has the potential to drive significant innovation."

Access to PDAOAI is enabled via PDAO tokens, which are initially distributed to eligible shareholders in 2023. Governance of the platform is managed through Pet2DAO, a decentralised autonomous organisation (DAO) designed to ensure transparent, community-driven decision-making without reliance on centralised authorities. This decentralised model further supports the platform’s goal of empowering users while maintaining accountability and fairness.